NR4A1 and breast carcinoma: Recognizing that hormonal receptors’ cut-offs (10%) are based on breast cancer data and, therefore, a potential source of bias, we sought to apply newer, more accurate cut-offs previously published by our group [11] pursuant to the recently published European Network for Individualized Treatment of Endometrial Cancer (ENITEC) collaboration study.